SCHEMBL4200808

SCHEMBL4200808

COc1ccc(N(Cc2cccnc2)c2cccc(S(=O)(=O)N3CCOCC3)c2)cc1OC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 5/20 0.56
PDE4D Q08499 4/20 0.56
PDE4B Q07343 3/20 0.56
PDE4C Q08493 3/20 0.56
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
POLB P06746 1/20 0.43
NPC1 O15118 1/20 0.43
GRM2 Q14416 2/20 0.42
MAPT P10636 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4193194 0.94 PDE4A (0.60) PDE4APDE4DPDE4BPDE4CKMT2A
SCHEMBL4200537 0.92 PDE4A (0.56) PDE4APDE4DPDE4BPDE4CKMT2A
SCHEMBL4204872 0.90 KMT2A (0.45) PDE4APDE4DPDE4BPDE4CKMT2A
SCHEMBL4197440 0.86 PDE4A (0.60) PDE4APDE4DPDE4BPDE4CKMT2A
SCHEMBL4193791 0.84 PDE4A (0.47) PDE4APDE4DPDE4BPDE4CKMT2A
SCHEMBL4192741 0.84 KMT2A (0.44) PDE4APDE4DPDE4BPDE4CKMT2A
SCHEMBL1157704 0.82 PDE4A (0.61) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL1157687 0.82 PDE4A (0.58) PDE4APDE4DPDE4BPDE4CGRM2
SCHEMBL1157497 0.81 PDE4A (0.62) PDE4APDE4DPDE4BPDE4C
SCHEMBL1157859 0.81 PDE4A (0.60) PDE4APDE4DPDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US claimed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US claimed
WO-2009067607-A2 COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS MEMORY PHARMACEUTICALS CORPORATION (US) 2009-05-28 WO disclosed
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
EP-1539697-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS Memory Pharmaceutical Corporation (US) 2005-06-15 EP disclosed
WO-2004009552-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 8/4885PDE4B 2/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A PDE4A 1/4885PDE4D 8/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.